Amylyx Pharmaceuticals Inc (AMLX) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $32.70 (-3.65%), Market cap $1.43B, 52-week low–high $4.72 ~ $18.36.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, wh
Financial statements, price targets, institutional (13F) holdings and related news for Amylyx Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Amylyx Pharmaceuticals Inc trades at $32.70 (-3.65%). Real-time quotes and charts are available on BlackAll Trade.
Amylyx Pharmaceuticals Inc has a market cap of about $1.43B.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the Unit